Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tan

Showing results (581-590 of 640) with videos related to

Pageof 64
Sort By:
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
International Journal of Radiation Oncology, Biology, Physics|October 15, 2021
Clinical Complete Response in Patients With Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Nonoperative ManagementRe-I Chin, Amit Roy, Katrina S Pedersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.
Nature Nanotechnology|June 27, 2018
Tailoring sample-wide pseudo-magnetic fields on a graphene-black phosphorus heterostructureYanpeng Liu, J N B Rodrigues, Yong Zheng Luo, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Real-Time CDC Consultation during the COVID-19 Pandemic-United States, March-July, 2020Daniel Wozniczka, Hanna B Demeke, Angela M Thompson-Paul, et al.
Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.
Pageof 64

Showing results (581-590 of 640) with videos related to

Sort By:
Pageof 64
Lancet (London, England)|March 24, 2009
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialRonald P Dematteo, Karla V Ballman, Cristina R Antonescu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitorAntoinette R Tan, Xiaowei Yang, Stephen M Hewitt, et al.
International Journal of Radiation Oncology, Biology, Physics|October 15, 2021
Clinical Complete Response in Patients With Rectal Adenocarcinoma Treated With Short-Course Radiation Therapy and Nonoperative ManagementRe-I Chin, Amit Roy, Katrina S Pedersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 studyS Adams, P Schmid, H S Rugo, et al.
Breast Cancer Research and Treatment|March 22, 2017
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancerJosé Baselga, Serafin M Morales, Ahmad Awada, et al.
Nature Nanotechnology|June 27, 2018
Tailoring sample-wide pseudo-magnetic fields on a graphene-black phosphorus heterostructureYanpeng Liu, J N B Rodrigues, Yong Zheng Luo, et al.
Breast Cancer Research and Treatment|December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II studyA R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2018
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 studyS Adams, S Loi, D Toppmeyer, et al.
International Journal of Environmental Research and Public Health|July 24, 2021
Real-Time CDC Consultation during the COVID-19 Pandemic-United States, March-July, 2020Daniel Wozniczka, Hanna B Demeke, Angela M Thompson-Paul, et al.
Breast Cancer Research and Treatment|July 7, 2017
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancerHope S Rugo, Olivier Trédan, Jungsil Ro, et al.
Pageof 64